Purple Biotech Q2 FY26 net income swings to USD 400,000; operating loss widens to USD 1.3 million
PPBT•Q2 results and expenses
- Purple Biotech posted IFRS net income of USD 0.4 million for Q2 2026, swinging from a net loss of USD 1.1 million a year earlier.
- IFRS operating loss widened to USD 1.3 million from USD 1.2 million, with R&D spending rising to USD 0.7 million from USD 0.6 million.
- IFRS finance income, net climbed to USD 1.7 million from USD 0.1 million on a higher non-cash gain from warrant revaluation.
Cash position and development plans
- Cash and cash equivalents and short-term deposits totaled USD 6.1 million at June 30, 2026, seen funding operations through mid-2027.
- IM1240 tri-specific antibody is aimed at entering clinical studies in 2027; management said it is pursuing a strategic collaboration and financing alternatives.
Related News
Replimune Group, Inc. <REPL.O>: Wedbush raises to outperform from neutral; raises target price to $19 from $12
REPL•
Ouster to present at Oppenheimer technology conference in upcoming investor events
OUST•
